Cargando…

CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance

Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Tian, Han, Yong, Yu, Ling, Ao, Sheng, Li, Ziyu, Ji, Jiafu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951414/
https://www.ncbi.nlm.nih.gov/pubmed/24622579
http://dx.doi.org/10.1371/journal.pone.0091771
_version_ 1782307119267053568
author Gao, Tian
Han, Yong
Yu, Ling
Ao, Sheng
Li, Ziyu
Ji, Jiafu
author_facet Gao, Tian
Han, Yong
Yu, Ling
Ao, Sheng
Li, Ziyu
Ji, Jiafu
author_sort Gao, Tian
collection PubMed
description Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNA2 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNA2 was closely associated with tamoxifen resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, though CCNA2-Drug interaction network, we demonstrated the interactions between CCNA2 and several available cancer drugs. Overall, we suggest that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy. It's also a promising target for developing new strategies to prevent or even reverse tamoxifen resistance. Moreover, CCNA2 expression may help monitoring tamoxifen efficacy and directing personalized therapies. Nevertheless, in vivo and in vitro experiments and multi-center randomized controlled clinical trials are still needed before its application in clinical settings.
format Online
Article
Text
id pubmed-3951414
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39514142014-03-13 CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance Gao, Tian Han, Yong Yu, Ling Ao, Sheng Li, Ziyu Ji, Jiafu PLoS One Research Article Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNA2 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNA2 was closely associated with tamoxifen resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, though CCNA2-Drug interaction network, we demonstrated the interactions between CCNA2 and several available cancer drugs. Overall, we suggest that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy. It's also a promising target for developing new strategies to prevent or even reverse tamoxifen resistance. Moreover, CCNA2 expression may help monitoring tamoxifen efficacy and directing personalized therapies. Nevertheless, in vivo and in vitro experiments and multi-center randomized controlled clinical trials are still needed before its application in clinical settings. Public Library of Science 2014-03-12 /pmc/articles/PMC3951414/ /pubmed/24622579 http://dx.doi.org/10.1371/journal.pone.0091771 Text en © 2014 Gao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gao, Tian
Han, Yong
Yu, Ling
Ao, Sheng
Li, Ziyu
Ji, Jiafu
CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
title CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
title_full CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
title_fullStr CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
title_full_unstemmed CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
title_short CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
title_sort ccna2 is a prognostic biomarker for er+ breast cancer and tamoxifen resistance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951414/
https://www.ncbi.nlm.nih.gov/pubmed/24622579
http://dx.doi.org/10.1371/journal.pone.0091771
work_keys_str_mv AT gaotian ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance
AT hanyong ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance
AT yuling ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance
AT aosheng ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance
AT liziyu ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance
AT jijiafu ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance